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Introduction
Between 1996 and 2000, the incidence
of malaria in South Africa, and in northern
KwaZulu-Natal in particular, increased
dramatically. For example, there were
5 991 notified malaria cases in South
Africa in 1995, whereas there were 61
934 in 2000.1 Ndumo Clinic, in northern
KwaZulu-Natal, is a satellite clinic of Mos-
vold Hospital situated in an area of high
malaria incidence. The number of malaria
cases detected at the clinic increased
from 637 in 1995 to 30 885 in 2000.2
In 2000, a study by Bredenkamp et
al at Ndumo Clinic found failure of treat-
ment with sulphadoxine/pyrimethamine
(SP), then a standard treatment for un-
complicated malaria, in at least 61% of
patients.3 In January 2001, SP ceased
to be issued by the Department of Health
Pharmaceutical and Medical Supplies
Centre for the treatment of malaria in
KwaZulu-Natal, and CoartemTM (20mg
artemether and 120mg lumefantrine –
Novartis South Africa (Pty) Ltd) became
the recommended treatment for uncom-
plicated malaria in non-pregnant patients
older than one year in KwaZulu-Natal.4
The failure of SP may have been
partly responsible for the increase in
malaria between 1996 and 2000. Regular
studies of the efficacy of SP prior to 2000
might have detected failure of the drug
earlier and permitted an earlier change
of treatment of falciparum malaria, de-
creasing the ensuing epidemic. This
view is echoed by Durrheim, Sharp and
Barnes in their editorial in the South
African Medical Journal.5
A standard WHO protocol for the
assessment of the therapeutic efficacy
of antimalarial drugs requires follow-up
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Summary
Background: A follow-up study was undertaken to assess the efficacy of CoartemTM tablets (20 mg artemether
and 120 mg lumefantrine – Novartis South Africa (Pty) Ltd) to clear plasmodium falciparum malaria parasitaemia
at a single 42-day follow-up, with 42 days being chosen in order to detect early emergence of resistance. The
study was performed at Ndumo Clinic and Mosvold Hospital in the Ingwavuma District of KwaZulu-Natal, South
Africa in January/February 2002.
Method: The study included 37 patients presenting to Ndumo Clinic and two presenting to Mosvold Hospital with
uncomplicated malaria diagnosed by symptoms and a positive immunochromographic test (ICT) for plasmodium
falciparum. The main outcome measures were Trophozoite counts on thick film and polymerase chain reaction
parasite analysis of blood spot at day 42.
Results: Only 31 of the 37 recruited patients were confirmed to be suffering from malaria by polymerase chain
reaction (PCR). Of the 31, 24 returned for follow-up. One patient had parasitaemia at day 33, but tested negative
at day 42 after re-treatment with Coartem™. It was not determined whether this patient was suffering from a
recrudescence or re-infection of falciparum malaria. All the other returning patients tested negative for falciparum
malaria on blood film and PCR examination.
Conclusions: CoartemTM still appears to be an effective treatment for falciparum malaria. Regular assessment
of its efficacy is desirable.                                       (SA Fam Pract 2004;46(6): 21-24)
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Audit of efficacy of CoartemTM to
clear plasmodium falciparum
malaria parasitaemia at single
forty-two day follow-up
of the patients on at least days 0, 1, 2,
3, 7 and 14.6 Substantial resources are
needed and it is difficult to prevent pa-
tients from dropping out.
With a previous audit of SP and chlo-
roquine (CQ) in October 2000,7
and an audit of Coartem™ in February
2001,8 a single 14-day follow-up of a
sample of patients was used as a quick
and simple assessment of the efficacy
of the existing regime. These audits
demonstrated a high failure rate of the
SP/CQ regime, but no resistance to
Coartem™. Fourteen days was chosen
because it is the latest interval at which
post-treatment parasitemia could be
confidently attributed to treatment failure,
rather than recrudescence, in the ab-
sence of sophisticated techniques, such
as polymerase chain reaction (PCR), to
distinguish different strains of parasite.
It takes 9-10 days from infection with
plasmodium falciparum to the appear-
ance of parasites in the blood (the pre-
patent period).9
However, according to Professor NJ
White, the early stage of development
of resistance to a combination drug re-
gime containing an artemisenin deriva-
tive is unlikely to be detected before 42
days, even using polymerase chain re-
action techniques, due to the number
of parasites being too low to be detected
before 42 days.10 A 14-day follow-up,
although being recommended as the
last day of follow-up in a WHO protocol,
is an insensitive test of parasite
resistance.6
PCR is a sensitive test for the pres-
ence of malaria parasite DNA, and is
also capable of distinguishing between
different strains, so that recrudescence
of malaria due to resistance to antima-
larial drugs can be distinguished from
re-infection. When PCR analysis was
offered by the Medical Research Coun-
cil’s Malaria Research Programme, it
was decided, for the above reasons, to
perform a single 42-day follow-up.
Study Population and Methods
Pre-study calculation of sample size
With the previous follow-up study of
Coartem™, shortly after its introduction,
no resistance was detected at 14 days
follow-up.8 At the time of the present
study, the drug had only been in use for
one year so it was not expected (nor
hoped) that resistance would be detect-
ed. A sample size of 30 with complete
returns and no malaria detected at follow-
up is large enough to be confident of a
failure rate of less than 10% (p=0.05),
whereas a sample size of 59 is needed
to be sure of a failure rate of less than
5% (p=0.05). The study was intended
to be cheap, quick and repeatable. The
study required medical staff time, a re-
source considered valuable, so it was
decided that only six days would be
spent recruiting patients, whom, it was
hoped, could all be followed up over six
days beginning 42 days later.
Exclusions
Patients with severe or complicated ma-
laria, pregnant women, patients younger
than five years and patients treated for
malaria during the previous two weeks
were excluded from the study.
Recruitment and methods
Thirty-seven self-presenting patients at
Ndumo Clinic and two at Mosvold Hospi-
tal, who had been diagnosed as suffering
falciparum malaria by positive immuno-
chromographic test (ICT) (KAT-Quick
Malaria Rapid Test for Plasmodium falci-
parum – Cape Biotech (Pty) Ltd ), were
assessed by a medical officer. Those not
excluded were asked, or in the case of
children, the accompanying adult was
asked, if they would be prepared to return
for a 42-day check. It was explained that
the object of the study was to find out
how well Coartem™ was working. Con-
sent was obtained in writing from patients
aged 14 or older, and in the case of
children younger than 14, from an accom-
panying adult. The consent form was
written in English and Zulu.
A thick blood film and blood sample
collected on filter paper for PCR analysis
was taken on the day of presentation,
after diagnosis of malaria with ICT.
Patients were given the recommend-
ed treatment for uncomplicated malaria
in KwaZulu-Natal, as shown in Table I.4
Patients were provided with a written
follow-up date, and offered R50 for trav-
elling expenses and a mosquito net on
return. Patients were told to return imme-
diately should their condition deteriorate,
and were informed that, if this should
happen, they would still receive travelling
expenses and a net.
Clinic staff were requested to refer
study patients with suspected treatment
failure to hospital. Upon their return, the
patients had their temperature taken,
were clinically assessed, and malaria
ICT, thick films and PCR samples were
taken. ICT was taken to be able to give
the patient a quick result.
Thick films were allowed to dry and
then stained with 10% Giemsa (5 ml
Giemsa diluted with 45 ml phosphate
buffer) for 10 minutes, rinsed with tap
water and air dried. The films were ex-
amined using 100x oil objective. Malaria
parasites were counted in conjunction
with 300 white cells. The number of par-
asites thus counted was multiplied by
25 to give an estimate of the number of
parasites per microlitre of blood.
Ethical considerations




Thirty-nine patients (37 from Ndumo Clinic
and two from Mosvold Hospital) were
recruited for the follow-up study. No pa-
tients refused to return when asked to
participate. The age-sex distribution of the
selected sample is as given in Figure 1.
Five patients weighed more than
65 kg.
Temperature at recruitment
The temperatures of the patients, taken
when they were recruited, are shown in
Table II.
Parasite count at recruitment
The parasite count measured when the
patients were recruited is shown in Table III.
      Parasite counts are shown divided
into classes as recommended in Essen-
tial Malariology.11 It was noticeable that
counts were higher than in previous
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Table I: Malaria treatment guidelines (uncomplicated falciparum malaria),
KwaZulu-Natal, 20014
Weight
10 - <15 kg
15 - <25 kg
25 - <35 kg
35+ kg
65+ kg*
Number of CoartemTM tablets per dose (given






studies in 2000 and 2001.7, 8
PCR results at
recruitment
Eight of the recruited patients
(seven from Ndumo, one from
Mosvold) were both PCR-
plasmodium falciparum neg-
ative and film-negative, and
were therefore not confirmed
malaria cases. The other 31
patients at recruitment, two of
whom were film negative, were
PCR positive, and therefore
were conf i rmed cases.
Follow-up results
The results of PCR at the fol-
low-up of the 31 patients with
confirmed malaria are sum-
marised in Table IV:
Of the 31 (30 from Ndumo, one
from Mosvold) patients with confirmed
falciparum malaria by PCR at recruit-
ment, 24 (23 from Ndumo, one from
Mosvold) returned for the follow-up. Un-
fortunately, seven patients did not return.
Of the 24 returning patients who had
initially been confirmed by PCR to be
suffering from malaria:
• Twenty-one (20 from Ndumo, one
from Mosvold) returned for only the
42-day follow-up. Four of these pa-
tients weighed more than 65 kg. All
were negative on film and PCR test.
• One woman, aged about 70 years,
attended on day 33. She was symp-
tomatic and was attended to by clinic
staff, but declined hospital referral.
Her ICT was positive and blood film
revealed a parasite count of 2080/µl.
Unfortunately, a blood spot was not
taken for PCR analysis. PCR was
attempted using the blood on the
slide to try to distinguish between
treatment failure and re-infection, but
falciparum malaria DNA was not ob-
tained from the small amount of blood
on the slide. She was retreated with
Coartem™ and was seen again nine
days later, when blood film and PCR
were both negative.
• One girl aged 10 returned at seven
days, when she was seen by clinic
staff. Her ICT was positive, but a
blood film was negative. She was,
however, retreated with Coartem™.
She was tracked down to re-attend
for further follow-up at day 49 after
her first treatment, when she was
thick film negative and PCR negative.
• One 45-year-old woman returned on
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Table IV: Patient follow-up results, Ndumo Clinic and Mosvold Hospital,
KwaZulu-Natal, March 2002
Falciparum malaria confirmed by PCR at recruitment
Film and PCR negative at day 42-45
Film and PCR negative at day 49 after re-treatment on
day 7 (although film negative)
Film positive at day 33. Film & PCR negative on day 42
after re-treatment with CoartemTM on day 33






Table III: Patient parasite counts at recruitment, Ndumo Clinic and Mosvold
Hospital, KwaZulu-Natal, January 2002






































Figure 1: Age-sex distribution of patients recruited for malaria treatment follow-up at
Ndumo Clinic and Mosvold Hospital, January 2002
Table II: Temperature of patients at recruitment, Ndumo Clinic and Mosvold
Hospital, KwaZulu-Natal, January 2002.
day 11 feeling unwell. She declined
hospital transfer. ICT was positive
but blood film was negative. She
was not retreated and, when she
returned on day 42, was thick film
negative and PCR negative.
ICT rapid test results at
follow-up
Rapid tests were performed at follow-
up to give a quick result to the returning
patients. However, 13 of the 24 returning
patients had weakly positive tests at
their final test, and one patient had a
strongly positive test, although all sam-
ples taken at the same time were film
and PCR negative. It appears that fol-
low-up rapid tests should be interpreted
cautiously, even at 42 days.
Conclusions
This study did not prove treatment failure
with the use of Coartem™ for plasmo-
dium falciparum malaria. The one pa-
tient among the 24 returning patients
who had parasites on day 33 may have
been re-infected. Her blood was film
and PCR negative nine days later (day
42) after re-treatment with Coartem™.
Twenty-three patients, one of whom
received two treatments, showed no
evidence of early emergence of resist-
ance to Coartem™.
Four returning patients weighed
more than 65 kg but were successfully
treated, despite a lack of data on the
efficacy of Coartem™ in patients weigh-
ing more than 65kg.4
Discussion
A WHO protocol stipulates 14 days as
the last day for antimalarial treatment
failure.6 However, authorities on malaria,
such as Professor NJ White (Welcome
– Mahidol – Oxford Malaria Research
Unit, Mahidol University, Thailand), con-
sider this to be an insensitive means of
detecting early stages of malaria para-
site resistance. If parasites are present
at 14 days, then the parasite has already
developed a high degree of resistance
to the drug and the drug has already
become virtually useless. Hence, a 14-
day follow-up, rather than being an early
warning system for the development of
drug resistance, is actually a too-late
warning system.  For this reason, a 42-
day follow-up was chosen to detect late
recrudescence, which occurs in the
early stages of the development of drug
resistance.
The study encountered a number of
difficulties:
• Enhanced malaria control in the area
had reduced the number of cases to
such an extent that recruitment in a
short period of time became difficult.
Whereas it would have been possible
to recruit more than 100 patients in
a single day in March 2000, by Jan-
uary 2002 only 37 patients could be
recruited in a week using a rapid
malaria test, and only 31 of these
were confirmed to be malaria cases
by microscopy and PCR.
• The discrepancy between the rapid
test performed by malaria control
programme personnel and micros-
copy and PCR may be due to a
number of reasons. However, the
study did not set out to assess the
rapid test and the authors are there-
fore not in a position to comment
fur ther on this discrepancy.
• Ndumo Clinic does not have perma-
nent medical staff. It had been en-
visaged that suspected early treat-
ment failures before 42 days would
be referred to Mosvold Hospital, 50
km away. However, the returning
patients declined to be referred. As
a result, there were instances of re-
treatment and the failure to obtain
PCR specimens from one patient,
which would have permitted differ-
entiating between a recrudescent
infection and re-infection. Better
contingency plans involving the per-
manent clinic nursing staff should
have been made for early returns.
• There was a substantial drop-out
rate – seven of the 31 confirmed
cases, which weakens the results.
Although a six-week follow-up is a
sensitive test of recrudescence, it
is also a long interval for a patient
to keep to, even with a financial
incentive.
Despite these weaknesses, it should
be kept in mind that, in 2000, there was
at least a 61% resistance rate to sul-
phadoxine/pyrimethamine, then the first-
line drug for malaria treatment.3 This
level of resistance would probably have
been detected in a study involving just
10 out of the tens of thousands of cases
per year occurring in northern KwaZulu-
Natal at the time. Twenty-three of the
24 returning patients showed no trace
of recrudescence at 42 days, from which
some comfor t  may be drawn.
Preventing patients from dropping
out is a difficulty which becomes even
greater in a study involving multiple
follow-up visits, as required by the WHO
protocol.6 Malaria tends to occur in poor
rural areas and the resources required
to trace non-returnees at their homes
are substantial. These resources may
be a deterrent to regular checks on
parasite resistance. Had regular studies
into malaria parasite drug resistance
been performed in KwaZulu-Natal from
1997 to 1999, when the malaria situation
was deteriorating rapidly, the failure of
sulphadoxine/pyrimethamine might
have been detected earlier and the
epidemic might have been curtailed.
Simple, cheap studies, repeated at reg-
ular intervals, would have a good
chance of detecting changes in parasite
sensitivity to antimalarial drugs.
The authors believe that regular
monitoring of antimalarial drug efficacy
is indicated in view of the history of





1. Source: Department of Health, Republic
of South Africa (10 January 2002).
2. Vaughan Williams CH. Success of insec-
ticide spraying in controlling malaria. S
Afr Med J 2003;93:167.
3. Bredenkamp BLF, Sharp BL, Mthembu
SD, Durrheim DN, Barnes KI. Failure of
sulphadoxine-pyrimethamine in treating
plasmodium falciparum malaria in Kwa-
Zulu-Natal Province. S Afr Med J
2001;91(11):970-72.
4. Barnes K, Malaria Advisory Group. Ma-
laria in KwaZulu-Natal. Guidelines for
the diagnosis and treatment of uncom-
plicated falciparum malaria in KwaZulu.
Falcon Press; 2001.
5. Durrheim DN,  Sharp BL, Barnes K. Sen-
tinel malaria surveillance – more than a
research  too l .  S A f r  Med J
2001;91(11):968-70.
6. World Health Organisation. Assessment
of therapeutic efficacy of antimalarial
drugs for uncomplicated falciparum ma-
laria in areas with intense transmission.
WHO/MAL/96.1077.
7. Vaughan Williams CH, La Cock C, Henry
GFJ, Ross AJ. Audit of failure rate of
sulfadoxine/pyrimethamine combined
with chloroquine to treat falciparum ma-
laria at single fourteen-day follow-up. SA
Fam Pract 2002;25(3):4-7.
8. Vaughan Williams CH, La Cock C, Henry
GFJ, Ross AJ. Audit of failure rate of
Coartem™ at single fourteen-day follow-
up. SA Fam Pract 2002;25(3):8-12.
9. Gilles HM, Warrell DA. Bruce-Chwatt’s
Essential Malariology. Third edition. Lon-
don: Arnold; 1996. p. 27.
10. White NJ. Welcome – Mahidol – Oxford
Malaria Research Unit, Mahidol Univer-
sity, Thailand. Development of malaria
drug resistance. Key note address. Pre-
sented at the South Africa 2001 Malaria
Conference Magoebaskloof. 26-28 No-
vember 2001.
11. Gilles HM, Warrell DA. Bruce-Chwatt’s
Essential Malariology. Third edition. Lon-
don: Arnold; 1996. p. 135.
Original Research
SA Fam Pract 2004;46(6)24
